BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JIN-A02 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JIN-A02\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07798921-2564@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:JIN-A02: Phase 1 readout est. (NCT07798921)
DESCRIPTION:JIN-A02\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: JIN-A02
  Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Fai
 lure\nEstimated primary completion: 1 June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/jin-a02#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07798921
URL:https://assetmemo.bio/drug/jin-a02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
